Jian Shen1, Jose M Ordovas. 1. Nutrition and Genomics Laboratory, Jean Mayer-USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA.
Abstract
BACKGROUND: Inflammation plays an instrumental role in all stages of atherosclerosis. High-sensitivity C-reactive protein (hsCRP), a systemic inflammatory marker, has been gaining recognition as an independent risk factor for cardiovascular disease (CVD). Both baseline hsCRP concentrations and drug-induced hsCRP changes are highly variable and potentially subject to genetic regulation. CONTENT: This review summarizes the current studies examining the effect of genetic and environmental factors on baseline plasma hsCRP concentrations, with a main focus on C-reactive protein, pentraxin-related (CRP) genetic polymorphisms and various dietary components that affect hsCRP concentrations. We also address the association of CRP genetic variations with CVD risk, a relationship that may support or refute the causality of CRP in the atherosclerotic process. Moreover, we discuss the impact of CRP genetic polymorphisms on hsCRP changes in response to 3-week fenofibrate treatment in the genetic intervention of the Genetics of Lipid Lowering Drugs and Diet Network study. SUMMARY: Genetic variants on the CRP locus and other loci and dietary and lifestyle factors are responsible for the interindividual variability of plasma hsCRP concentrations. CRP genetic variants further influence differing plasma hsCRP response after 3-week fenofibrate treatment in patients with metabolic syndrome. Future studies focusing on the influence and interaction of genetic variation on the hsCRP response to dietary and other behavior modification as well as drug treatment could have important implications for the development of more personalized preventive and therapeutic approaches to reduce CVD.
BACKGROUND:Inflammation plays an instrumental role in all stages of atherosclerosis. High-sensitivity C-reactive protein (hsCRP), a systemic inflammatory marker, has been gaining recognition as an independent risk factor for cardiovascular disease (CVD). Both baseline hsCRP concentrations and drug-induced hsCRP changes are highly variable and potentially subject to genetic regulation. CONTENT: This review summarizes the current studies examining the effect of genetic and environmental factors on baseline plasma hsCRP concentrations, with a main focus on C-reactive protein, pentraxin-related (CRP) genetic polymorphisms and various dietary components that affect hsCRP concentrations. We also address the association of CRP genetic variations with CVD risk, a relationship that may support or refute the causality of CRP in the atherosclerotic process. Moreover, we discuss the impact of CRP genetic polymorphisms on hsCRP changes in response to 3-week fenofibrate treatment in the genetic intervention of the Genetics of Lipid Lowering Drugs and Diet Network study. SUMMARY: Genetic variants on the CRP locus and other loci and dietary and lifestyle factors are responsible for the interindividual variability of plasma hsCRP concentrations. CRP genetic variants further influence differing plasma hsCRP response after 3-week fenofibrate treatment in patients with metabolic syndrome. Future studies focusing on the influence and interaction of genetic variation on the hsCRP response to dietary and other behavior modification as well as drug treatment could have important implications for the development of more personalized preventive and therapeutic approaches to reduce CVD.
Authors: Isabella Kardys; Moniek P M de Maat; André G Uitterlinden; Albert Hofman; Jacqueline C M Witteman Journal: Eur Heart J Date: 2006-05-03 Impact factor: 29.983
Authors: Mark B Pepys; Gideon M Hirschfield; Glenys A Tennent; J Ruth Gallimore; Melvyn C Kahan; Vittorio Bellotti; Philip N Hawkins; Rebecca M Myers; Martin D Smith; Alessandra Polara; Alexander J A Cobb; Steven V Ley; J Andrew Aquilina; Carol V Robinson; Isam Sharif; Gillian A Gray; Caroline A Sabin; Michelle C Jenvey; Simon E Kolstoe; Darren Thompson; Stephen P Wood Journal: Nature Date: 2006-04-27 Impact factor: 49.962
Authors: Ahmad Esmaillzadeh; Masoud Kimiagar; Yadollah Mehrabi; Leila Azadbakht; Frank B Hu; Walter C Willett Journal: Am J Clin Nutr Date: 2006-12 Impact factor: 7.045
Authors: Winfried März; Hubert Scharnagl; Michael M Hoffmann; Bernhard O Boehm; Bernhard R Winkelmann Journal: Eur Heart J Date: 2004-12 Impact factor: 29.983
Authors: Hind Berrahmoune; Bernard Herbeth; John V Lamont; Daniel Lambert; Stefan Blankenberg; Laurence Tiret; Peter S FitzGerald; Gérard Siest; Sophie Visvikis-Siest Journal: Clin Chem Lab Med Date: 2007 Impact factor: 3.694
Authors: Laura K Stewart; Michael G Flynn; Wayne W Campbell; Bruce A Craig; J Paul Robinson; Kyle L Timmerman; Brian K McFarlin; Paul M Coen; Erin Talbert Journal: Med Sci Sports Exerc Date: 2007-10 Impact factor: 5.411
Authors: Stella Aslibekyan; Edmond K Kabagambe; Marguerite R Irvin; Robert J Straka; Ingrid B Borecki; Hemant K Tiwari; Michael Y Tsai; Paul N Hopkins; Jian Shen; Chao-Qiang Lai; Jose M Ordovas; Donna K Arnett Journal: Pharmacogenet Genomics Date: 2012-03 Impact factor: 2.089
Authors: Satish A Eraly; Caroline M Nievergelt; Adam X Maihofer; Donald A Barkauskas; Nilima Biswas; Agorastos Agorastos; Daniel T O'Connor; Dewleen G Baker Journal: JAMA Psychiatry Date: 2014-04 Impact factor: 21.596
Authors: Carolina Muniz Carvalho; Frank R Wendt; Adam X Maihofer; Dan J Stein; Murray B Stein; Jennifer A Sumner; Sian M J Hemmings; Caroline M Nievergelt; Karestan C Koenen; Joel Gelernter; Sintia I Belangero; Renato Polimanti Journal: Neuropsychopharmacology Date: 2020-03-16 Impact factor: 7.853